Radiothérapie conformationnelle avec modulation d’intensité dans les carcinomes bronchiques non à petites cellules

Ayadi, M.; Zahra, N.; Thariat, Juliette; Bouilhol, G.; Boissard, P.; Houtte, Paul Van; Claude, L.; Mornex, F.

doi:10.1016/j.canrad.2014.06.009

Cited by 11 publications

(4 citation statements)

References 69 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the increasing radiation dose of external radiation could significantly improve the local control rate, it will inevitably lead to damage of normal tissue simultaneously, and the lowest effective dose could not be reached 27. These factors resulted in locally advanced NSCLC recurrence and distant metastasis.…”

Section: Discussionmentioning

confidence: 99%

<sup>125</sup>I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

Shen

Fan

Zhao

et al. 2017

OTT

View full text Add to dashboard Cite

ObjectivesThe objective of this study was to assess the efficacy of computed tomography (CT)-guided 125I brachytherapy alone in improving the survival and quality of life of patients with unresectable locally advanced non-small-cell lung cancer (NSCLC) after one cycle of first-line chemotherapy.Patients and methodsSixteen patients with locally advanced NSCLC were treated with CT-guided 125I brachytherapy after one cycle of first-line chemotherapy (group A). Sixteen patients who received only best supportive care (group B) were matched up with the patients in group A. Primary end point included survival, and secondary end point included assessment of safety, effectiveness of CT-guided 125I brachytherapy, and improvement in the quality of life.ResultsThe two groups were well balanced in terms of age, disease histology, tumor stage, tumor location, and performance status (P>0.05). The median follow-up time was 16 months (range, 3–30). The total tumor response rate was 75.0% in group A, which was significantly higher than that in group B (0.0%) (P<0.01). The median progression-free survival time was 4.80 months for patients in group A and 1.35 months for patients in group B (P<0.001). Kaplan–Meier survival analysis showed that the median survival time of group A was 9.4±0.3 months versus 8.4±0.1 months in group B (P=0.013). Tumor-related symptoms of patients were significantly relieved, and the quality of life was markedly improved in group A than in group B.ConclusionCT-guided 125I brachytherapy improved the survival of patients with locally advanced NSCLC and quality of life after one cycle of first-line chemotherapy compared with best supportive care.

show abstract

Section: Discussionmentioning

confidence: 99%

<sup>125</sup>I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

Shen

Fan

Zhao

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…However, because of normal tissue damage and long-term external irradiation, especially for tumor tissue involving vital organs (heart, great vessels, trachea, esophagus, and spine), significantly less radiation doses are administered to the tumor tissue. 33 Even with the use of advanced technology, including the development of image guided radiotherapy (IGRT), stereotactic ablative body radiotherapy (SABR), and intensity modulated radiotherapy (IMRT), the lowest effective dose could not be reached, leading to treatment failure.…”

Section: Discussionmentioning

confidence: 99%

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Xiang

Liu

et al. 2015

Medicine

View full text Add to dashboard Cite

To investigate the safety and effectiveness of computed tomography (CT)-guided 125I seed implantation for locally advanced nonsmall cell lung cancer (NSCLC) after progression of concurrent radiochemotherapy (CCRT).We reviewed 78 locally advanced NSCLC patients who had each one cycle of first-line CCRT but had progressive disease identified from January 2006 to February 2015 at our institution. A total of 37 patients with 44 lesions received CT-guided percutaneous 125I seed implantation and second-line chemotherapy (group A), while 41 with 41 lesions received second-line chemotherapy (group B).Patients in group A and B received a total of 37 and 41 first cycle of CCRT treatment. The median follow-up was 19 (range 3–36) months. After the second treatment, the total response rate (RR) in tumor response accounted for 63.6% in group A, which was significantly higher than that of group B (41.5%) (P = 0.033). The median progression-free survival time (PFST) was 8.00 ± 1.09 months and 5.00 ± 0.64 months in groups A and B (P = 0.011). The 1-, 2-, and 3-year overall survival (OS) rates for group A were 56.8%, 16.2%, and 2.7%, respectively. For group B, OS rates were 36.6%, 9.8%, and 2.4%, respectively. The median OS time was 14.00 ± 1.82 months and 10.00 ± 1.37 months for groups A and B, respectively (P = 0.059). Similar toxicity reactions were found in both groups. Tumor-related clinical symptoms were significantly reduced and the patients’ quality of life was obviously improved.CT-guided 125I seed implantation proved to be potentially beneficial in treating localized advanced NSCLC; it achieved good local control rates and relieved clinical symptoms without increasing side effects.

show abstract

“…It is particularly indicated for "superior sulcus" (Pancoast tumors), paravertebral and paracardiac tumors and in complex clinical situations in which conformal radiotherapy does not enable the release of non-toxic doses to organs at risk. 24 IMRT significantly reduces the risk of worsening quality of life in lung cancer patients undergoing radiation therapy.…”

Section: (B)mentioning

confidence: 99%

Guidelines for the treatment of lung cancer using radiotherapy

Chen

Novaes

Gadia

et al. 2017

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

Radiothérapie conformationnelle avec modulation d’intensité dans les carcinomes bronchiques non à petites cellules

Cited by 11 publications

References 69 publications

<sup>125</sup>I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

<sup>125</sup>I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Guidelines for the treatment of lung cancer using radiotherapy

Contact Info

Product

Resources

About

Radiothérapie conformationnelle avec modulation d’intensité dans les carcinomes bronchiques non à petites cellules

Cited by 11 publications

References 69 publications

<sup>125</sup>I&nbsp;brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

<sup>125</sup>I&nbsp;brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Guidelines for the treatment of lung cancer using radiotherapy

Contact Info

Product

Resources

About

<sup>125</sup>I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care

<sup>125</sup>I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy：a comparison with best supportive care